After Another Strong Quarter, WuXi Aims To Become Backbone Of China’s Life Science Industry: China Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Despite a macroeconomic slowdown, China’s leading CRO reported another strong quarter due to increasing demand for R&D services from both international and domestic companies.
You may also be interested in...
China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
China's Leading CRO WuXi Looks To Utilize Manufacturing Capacity With Telaprevir
SHANGHAI - Leading Chinese contract research organization WuXi PharmaTech Co., Ltd. recorded a strong quarter with revenue up 16% over the same period last year to $93.6 million, and the company is readying itself for big increases in its manufacturing business thanks to large-scale contracts generated from discovery deals
Are China's Rising Labor Costs Good For Big Pharma?
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market